Board of directors

 

Anders Ekblom

Anders Ekblom – born 1954, Chairman since 2021 and Board member since 2017 – is a physician, board certified in anaesthesia and intensive care, dentist and Associate Professor in physiology at the Karolinska Institute. Anders Ekblom has extensive experience from the biopharmaceutical industry globally, including being EVP Global Medicines Development at AstraZeneca and CEO and president of AstraZeneca AB Sweden.

Other current positions: Chairman of Atrogi AB, Elypta AB and Xspray Pharma AB. Board member of AnaMar AB and Mereo BioPharma Group plc.

Holdings in Alligator: 93,172 shares and 100,000 warrants in program TO 2022/2025 II.

Independent in relation to the Company, its senior management and major shareholders.

Hans-Peter Ostler

Hans-Peter Ostler - born 1971, Vice chairman since 2021 – has University studies in economics and law etc. at the School of Business, Economics and Law and School of Public Administration at Gothenburg University and currently works as wealth manager at Söderberg & Partners. Hans-Peter Ostler has more than 20 years of experience in investment banking and private banking, including from Danske Bank. Hans-Peter Ostler’s previous experiences include assignments such as board member of IRLAD Therapeutics AB.

Other current positions: Board member of Oblique Therapeutics AB, of S.P. HMSO Göteborg AB, of Promore Pharma and InorbitTX.

Holdings in Alligator: 700,000 shares and 100,000 warrants in program TO 2022/2025 II.

Independent in relation to the Company, its senior management and major shareholders.

Graham Dixon

Graham Dixon – born 1961, Board member since 2019 - has a PhD in biochemistry from Swansea University and is the CSO/head of R&D at Mithra Pharmaceuticals. Graham Dixon has extensive experience in discovering and developing novel drugs, with applications for both orphan and mainstream disease indications. Previous experiences include inter alia CEO Neem Biotech, head of R&D and CSO of Onxeo, Galapagos, Sensorion Pharma and Addex Therapeutics.

Other current positions: Chairman of Apaxen BV.

Holdings in Alligator: None

Independent in relation to the Company, its senior management and major shareholders.

 

Eva Sjökvist Saers

Eva Sjökvist Saers - born 1962, Board member since 2021 - has a Doctoral degree in pharmaceutical science from Uppsala University. Eva Sjökvist Saers has many years of experience from the pharmaceutical industry where she has worked in various leading positions within Astra/AstraZeneca, Apoteket AB and as CEO of the pharmaceutical company Apotek Produktion & Laboratorier AB (APL) for more than 10 years. Eva Sjökvist Saers is also Chairman of the strategic innovation area Swelife and has previously been Chairman of Apotekarsocieteten and Vice Chairman of SwedenBIO.

Other current positions: Chairman of the board of Dicot AB (publ). Board member of Bluefish Pharmaceuticals AB (publ), IDL Biotech AB (publ), Oxcia AB and Apoex AB. Deputy board member of Brainstorm Aktiebolag.

Holdings in Alligator: 100,000 warrants in program TO 2022/2025 II.

Independent in relation to the Company, its senior management and major shareholders.

Veronica Wallin

Veronica Wallin - born 1986, Board member since 2021 – has a Master of Science in Business and Economics from Stockholm University. Veronica Wallin is the CFO at the medical technology company Episurf Medical AB since 2017. Veronica Wallin has previously, among other things, been CFO at the pharmacy company ApoEx AB.

Other current positions: Board member for a number of subsidiaries within the Episurf Group.

Holdings in Alligator: 31,250 shares and 100,000 warrants in program TO 2022/2025 II.

Independent in relation to the Company, its senior management and major shareholders.

Staffan Encrantz

Staffan Encrantz - born 1951, Board member since 2022 – has a Law degree (Summa Cum Laude) from Uppsala University, Sweden. Staffan Encrantz, is the founder and president of Allegro Investment, Inc., a company based in Menlo Park, California, which manages a $750 million investment portfolio. He has actively led investments in and operation of a variety of companies for over 30 years and has led the growth and development of both early-stage companies and established businesses in a wide variety of fields. Additionally, Staffan has extensive experience in commercial real estate, primarily in Sweden and USA, and of the hedge fund industry as representing substantial investors in a number of hedge funds and as former Board member of MKM Longboat Multi Strategy Fund Ltd. as well as a Board member of Harbour Solutions Group Ltd.

Other current positions: Chairman of AnaMar AB, Sweden, a company engaged in the research and development of drugs for fibrosis, Koncentra Verkstads AB, Sweden, a contract manufacturing group, Nclear Inc., Atlanta GA, a company working with environmental clean-up, Oxymetal SAS, France a laser and plasma steel cutting business and Sight Sciences Inc., Menlo Park CA, an eye care company developing and selling devices for surgical treatment of glaucoma and dry eye. Board member of Harbour Solutions Ltd, London, England, a dispute funding and insurance business and Chairman of GovX Inc. San Diego, CA an e-commerce company.

Holdings in Alligator: 55,642,092 shares

Independent in relation to the Company and its senior management.

Denise Goode

Denise Goode - born 1958, Board member since 2022 – has a Bachelor of Science (Honours) in zoology from the University of Manchester, UK. Fellow of the Institute of Chartered Accountants in England and Wales. Denise Goode, brings a wealth of financial, commercial, and life science industry experience, both from her extensive career as a senior pharmaceutical executive and from board and advisory roles held in life sciences since 2008. She has a deep understanding of the pharmaceuticals sector, finance and fundraising, and is highly experienced in business development. Previously, she had a 20 year career with AstraZeneca Pharmaceuticals PLC where she held global senior leadership roles within both finance and commercial activities. Denise is a PwC alumnus.

Other current positions: CEO of QED Life Sciences Limited, a consultancy company advising and supporting the strategic direction of biotech companies and providing business mentoring to CEOs and senior leaders. Board member of Abliva AB (publ) where she is chair of the remuneration committee and a member of the audit committee. VP, Business Development at AnaMar AB. Certified COVID vaccinator for the UK National Health Service..

Holdings in Alligator: 100,000 warrants in program TO 2022/2025 II.

Independent in relation to the Company, its senior management and major shareholders.

Laura von Schantz

Laura von Schantz - born 1982, Board member since 2017 - is a Swedish graduate engineer in biotechnical engineering and has a doctorate in immuno-technology from Lund University. Is the board’s employee representative.

Other current positions: None

Holdings in Alligator: 2,626 shares and 77,000 warrants in program TO 2022/2025 I.

Independent in relation to major shareholders.

Updated 12 July 2022